Glioblastoma multiforme metastases to the masticator muscles and the scalp

Pérez-Bovet, Jordi; Rimbau-Muñoz, Jordi

doi:10.1016/j.jocn.2018.04.021

Cited by 10 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In primary solid organ cancers, the existence of CTCs is linked to dissemination and metastatic spread. Extracranial metastases though rare in GLI-M, have been reported previously (21)(22)(23)(24)(25). The detection of circulating (malignant) glial cells (CGCs) in blood samples from patients with GLI-M appears to indicate that while CGCs can enter circulation, they may be unable to find a target tissue where they can egress, survive, and grow (26).…”

Section: Discussionmentioning

confidence: 99%

Profiling of circulating glial cells allows accurate blood-based diagnosis of glial malignancies

O’Neill

Syed

Crook

et al. 2022

Preprint

View full text Add to dashboard Cite

Diagnosis of primary glial malignancies (GLI-M) in individuals presenting with Intracranial Space Occupying Lesions (ICSOL) is based on histopathological evaluation (HPE) of tissue obtained by surgical resection or biopsy with attendant resource implications and risks. Approximately 70% of ICSOLs have non-malignant etiology and distinction from malignant lesions rests largely on HPE. Furthermore, GLI-M must be differentiated from metastatic lesions to the brain arising from solid tumors in other organs. We describe a blood-based test which detects GLI-M with high sensitivity and differentiates it from benign brain tumours (BBT) and brain metastases. The test is based on fluorescent multiplexed immunocytochemical (ICC) profiling for identification of Circulating Glial Cells (CGCs) and Circulating (Epithelial) Tumor Cells (CTCs) enriched from peripheral blood. The performance characteristics of the test were established in analytical validation as well as clinical studies. In an initial case-control study with discrete training (n = 31 BBT and n = 101 GLI-M) and test (n = 13 BBT and n = 44 GLI-M) sets, our platform showed 100% sensitivity and 100% specificity in identifying and differentiating GLI-M from BBT in the test set. In a prospective study of 68 individuals presenting with ICSOL, the test had 100% sensitivity and 100% specificity for identifying and differentiating GLI-M (n = 56) and BBT (n = 12). Finally, in a subset analysis of 586 samples, the test accurately identified samples from GLI-M (n = 40), BBT (n = 22), epithelial malignancies (EPI-M, n = 24) and healthy individuals (n = 500), with no false positive or false negative findings. The performance characteristics of this blood-based platform support its utility in clinical practice for diagnostic triaging of individuals presenting with ICSOL and facilitating more effective diagnosis compared to standard of care.

show abstract

Section: Discussionmentioning

confidence: 99%

Profiling of circulating glial cells allows accurate blood-based diagnosis of glial malignancies

O’Neill

Syed

Crook

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Extracranial glioblastoma dissemination is rare [1][2][3][4][5][6][7][8]. Scalp dissemination may occur through direct extension or seeding from intracranial lesions through the craniotomy defect.…”

Section: Discussionmentioning

confidence: 99%

Multimodal MRI of Extracranial Glioblastoma Dissemination

Venier¹,

Roccatagliata²,

Cianfoni³

et al. 2018

Neurosurg Cases Rev

View full text Add to dashboard Cite

“…Chang et al (81) present a pathologically proven patient with scalp metastasis, which was metastasized from LGG occurring site to the surgical scar. And GBM metastases to the masticatory muscles and the scalp (82). There was even a case of a female patient with a known glioblastoma who was detected to harbor multiple metastases in the bones, lung, pleura, liver, mesentery, and the subcutaneous soft tissue (83).…”

Section: Rare Extracranial Metastasesmentioning

confidence: 99%

Circulating Tumor Cells for Glioma

Zhang

Yuan

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Liquid biopsy has entered clinical applications for several cancers, including metastatic breast, prostate, and colorectal cancer for CTC enumeration and NSCLC for EGFR mutations in ctDNA, and has improved the individualized treatment of many cancers, but relatively little progress has been made in validating circulating biomarkers for brain malignancies. So far, data on circulating tumor cells about glioma are limited, the application of circulating tumor cells as biomarker for glioma patients has only just begun. This article reviews the research status and application prospects of circulating tumor cells in gliomas. Several detection methods and research results of circulating tumor cells about clinical research in gliomas are briefly discussed. The wide application prospect of circulating tumor cells in glioma deserves further exploration, and the research on more sensitive and convenient detection methods is necessary.

show abstract

Glioblastoma multiforme metastases to the masticator muscles and the scalp

Cited by 10 publications

References 6 publications

Profiling of circulating glial cells allows accurate blood-based diagnosis of glial malignancies

Profiling of circulating glial cells allows accurate blood-based diagnosis of glial malignancies

Multimodal MRI of Extracranial Glioblastoma Dissemination

Circulating Tumor Cells for Glioma

Contact Info

Product

Resources

About